IP Library Granted Patent US 9,938,560
Granted Patent B2
US 9,938,560 · App. 14/376,613 · Granted Apr 10, 2018

Methods for identifying modulators of Ras using nonlinear techniques

Inventors: Joshua S. Salafsky (San Francisco, CA); Ryan P. McGuinness (Tiburon, CA)
Assignee: Biodesy, Inc.
C12Q1/34C07K14/82C12Q1/42G01N2333/82G01N2333/916G01N2440/00G01N2458/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,938,560
App. No.
14/376,613
Granted
Apr 10, 2018
Kind
B2
Abstract

Provided herein are compositions and methods for identifying and detecting modulators of Ras protein conformational states through the use of second harmonic generation (SHG) technology. Also provided herein are methods for detecting a conformational changes in the three dimensional structure of a protein bound to a supported lipid bilayer.

Claims (13)

1. A method for identifying an agent that induces a conformational change of a target protein, the method comprising:

a. contacting the target protein with the agent, wherein the target protein is bound to a binding partner, and wherein the binding partner is selected from the group consisting of a second harmonic generation (SHG)-active labeled GDP, an SHG-active labeled GDP analog, an SHG-active labeled GTP, and an SHG-active labeled GTP analog that has a net orientation at an interface; and

b. detecting a conformational change in the structure of the target protein induced when the agent binds to the target protein by analyzing a detectable signal generated by the SHG-active label using a surface selective technique.

2. The method of claim 1 , wherein the target protein is a G protein-coupled receptor (GPCR).

3. The method of claim 1 , wherein the target protein is a wild type or mutant Ras protein.

4. The method of claim 1 , wherein the interface is selected from the group consisting of a glass surface, a polyethylene glycol surface, a supported lipid bilayer surface, a lipid analog bilayer surface, a plastic surface, a metal surface, a latex surface, a rubber surface, a ceramic surface, a polymeric surface, a polypropylene surface, a polyvinylidene difluoride surface, and a polyethylene surface.

5. The method of claim 4 , wherein the interface is derivatized with oligo-PEG molecules or lipids.

6. The method of claim 5 , wherein the oligo-PEG molecules or lipids are Ni-NTA-bearing oligo-PEG molecules or Ni-NTA-bearing lipids.

7. The method of claim 5 , wherein the interface is a supported lipid bilayer or a lipid analog bilayer.

8. The method of claim 1 , wherein the target protein comprises an affinity tag.

9. The method of claim 1 , wherein the agent is a small molecule chemical compound, an antibody, a non-antibody polypeptide, a carbohydrate, an inhibitory nucleic acid, or any combination thereof.

10. The method of claim 1 , wherein the second harmonic generation (SHG)-active label is (1-(2-Maleimidylethyl)-4-(5-(4-Methoxyphenyl)Oxazol-2-yl) Pyridinium Methanesulfonate) or PyMPO-succinimidyl ester.

11. The method of claim 7 , wherein the target protein comprises a His-tag.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2021
From: BLUELIGHT THERAPEUTICS, INC.
To: QUANTA THERAPEUTICS, INC.
Reel/Frame 057721/0206 →
CHANGE OF NAME Recorded Jun 24, 2020
From: BIODESY, INC.
To: BLUELIGHT THERAPEUTICS, INC.
Reel/Frame 053834/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2015
From: SALAFSKY, JOSHUA; MCGUINNESS, RYAN P.
To: BIODESY, INC.
Reel/Frame 034997/0632 →
Continuity (3)
Provisional Application 61595123 · Feb 5, 2012
Provisional Application 61638026 · Apr 25, 2012
Related Publication 20150051110A1 · Feb 19, 2015